An uplisting is a milestone, not the finish line. As U.S. cannabis companies gain access to major public exchanges, what will it take for institutional capital to truly enter the space? This panel explores the remaining barriers—from federal policy and investment mandates to liquidity, governance and market maturity—and what operators and investors should expect as cannabis capital markets enter their next chapter.